Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MannKind, Sanofi end Afrezza agreement
February 2016
EDIT CONNECT

SHARING OPTIONS:

VALENCIA, Calif.—MannKind Corporation has terminated its license and collaboration agreement with sanofi-aventis U.S. LLC for the development and commercialization of Afrezza (insulin human) Inhalation Powder. The termination of the deal in its entirety will be effective no later than six months from the date of Sanofi’s notice of termination, or July 4, 2016. In the wake of this change of direction, MannKind has announced it is reviewing its strategic options for Afrezza, which is a rapid-acting inhaled insulin therapy indicated for the improvement of glycemic control in adults patients with diabetes mellitus. MannKind and Sanofi first announced the license and collaboration agreement on August 11, 2014, with Sanofi assuming responsibility for global commercial, regulatory and development activities and MannKind manufacturing Afrezza under a separate supply agreement.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.